Jul. 8 at 1:46 PM
$ELTP $JNJ $PFE $GME
Elite’s massive 77% revenue jump to
$148.9 million in fiscal year 2026 was driven by its booming generic portfolio:Generic Vyvanse (Lisdexamfetamine): This commercial launch was the single largest catalyst for the record-breaking year, capturing a substantial double-digit market share.Nostrum Asset Acquisition: ELTP recently commercialized its newly acquired Methadone Hydrochloride tablets, further widening its commercial pain-management footprint.The
$20 Billion Pipeline: As highlighted on the ELTP Reddit Board, retail bulls are now focused on Elite's ongoing pivotal bioequivalence studies targeting heavy-hitting drugs like Januvia, Xeljanz, Ibrance, and Xtandi.
